Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, ...

Fintel reports that on November 8, 2024, Goldman Sachs upgraded their outlook for BioNTech SE - Depositary Receipt () ...

In a report released yesterday, Chris Shibutani from Goldman Sachs upgraded BioNTech SE (BNTX – Research Report) to a Buy, with a price ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

BioNTech SE (BNTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yaron Werber ...

On Monday, BioNTech SE (NASDAQ:BNTX) reported third-quarter revenues of 1.244 billion euros (or $1.36 billion), up from 895.3 ...

BioNTech SE (BNTX) reports strong revenue growth and pipeline progress, while navigating financial and legal hurdles.

Shares of BioNTech (BNTX) gained in pre-market trading after the company reported better-than-expected Q3 earnings. The biotech company’s earnings increased by 22.7% to €0.81 ($0.89 ...

Welcome to BioNTech's third quarter 2024 earnings call. I would like to hand the call over to Michael Horowicz director, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...